Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Dec 10, 2021 10:10pm
118 Views
Post# 34221026

RE:RE:RE:Best of luck hope agn gets nasdaq and goes to $20

RE:RE:RE:Best of luck hope agn gets nasdaq and goes to $20

What's simple to understand is the current market cap is a paltry figure compared to current analysts who cover Nasdaq stocks. Algernon will be one of only a few companies with DMT in human clinical trials come January 2022. See GH Research regarding its DMT program in Phase 2 human clinical trial. Nasdaq analysts place a market cap valuation north of 3 Billion $ CAD. GH Research current market cap is 1.6 Billion CAD. 


Algernon also has a stand-alone Chronic Cough human clinical trial starting this year. There's only one other company currently at Phase 2 for Chronic Cough. Bellus Health has been talked up by Algernon as a comparison for a longtime now. The analysts who cover Nasdaq stocks place a market cap valuation north of 1 Billion CAD. Bellus Health current market cap is 560 Million $ CAD.


The above numbers are not fiction. It's facts and Algernon falls among those companies chasing after treatments with their respective lead drug candidates. Somehow, people on the CSE and OTC fail to see a picture bigger than anything trading around pennies. It's the primary reason Algernon is moving to the Nasdaq. It's there where Algernon's current value will be unlocked and unchained from those who don't understand a thing about biotech companies and their progressive value.


I'm not here to arh=gue with anyone about hown Algernon should be valued by investors who don't understand business 101. Let alone how to see the pending trajectory of the stock price once listed on Nasdaq. The overall narrative will be out of the hands of the likes of those who exclusively trade penny stocks on the CSE and OTC. Those type of investors live in a small world and think in terms of small gains. Somebody gotta make a killing on investments and anyone following the real story about Algernon's chances knows the current market cap is absurdly ridiculous compared to any biotech company that trades on any exchange.


Algernon is long past due to turn the page on the bottom feeder penny stock market and start swimming with the real sharks and whales in the biotech world.

 
<< Previous
Bullboard Posts
Next >>